How this ETF's holdings score on the six lenses, weighted by holding weight. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
Trend
PHARMABEES daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.
Relative strength
PHARMABEES ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 21.29% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DIVISLAB | Pharma | 10.34% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| CIPLA | Pharma | 8.37% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| TORNTPHARM | Pharma | 7.59% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| LAURUSLABS | Pharma | 7.14% | 9 | 9 | 3 | 3 | 1 | — | +29.2% |
| DRREDDY | Pharma | 7.07% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| LUPIN | Pharma | 5.93% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| AUROPHARMA | Pharma | 4.42% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| ALKEM | Pharma | 3.40% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| GLENMARK | Pharma | 3.40% | 10 | 9 | 9 | 4 | 3 | — | +8.2% |
| BIOCON | Pharma | 3.07% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| ZYDUSLIFE | Pharma | 2.85% | 9 | 10 | 10 | 2 | 8 | — | +1.9% |
| MANKIND | Pharma | 2.82% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| IPCALAB | Pharma | 2.45% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| GLAND | Pharma | 2.02% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| SAILIFE | Healthcare | 1.83% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| WOCKPHARMA | Pharma | 1.64% | 10 | 3 | 3 | 8 | 1 | Leader | +12.2% |
| AJANTPHARM | Pharma | 1.47% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| ABBOTINDIA | Pharma | 1.46% | 3 | 9 | — | 6 | 8 | — | -3.8% |
| PPLPHARMA | Pharma | 1.23% | 10 | 1 | 5 | 9 | 5 | Leader | +28.4% |
Native from atlas_foundation — the lens journal looked through de_etf_holdings; identity from Morningstar (de_mf_master). ← Back to ETFs